Treatment News : Opioid Substitution Therapy Is Linked to Lowered HIV Risk

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 9, 2014

Opioid Substitution Therapy Is Linked to Lowered HIV Risk

Two opioid substitution therapies—methadone maintenance therapy and buprenorphine-naloxone treatment—both lower injecting behaviors that put injection drug users (IDUs) at risk for HIV, aidsmap reports. Publishing their findings in the Journal of Acquired Immune Deficiency Syndromes, researchers recruited 731 IDUs between May 2006 and October 2009 and then followed them until August 2010.

Under a 2-to-1 randomization scheme, 391 participants received methadone and 340 received buprenorphine. Upon their entry into the study, the participants completed a survey on behaviors that put them at risk for HIV during the previous 30 days. They repeated the survey 12 and 24 weeks later.

Both of the therapies were linked with a drop in frequency of injecting drugs. In addition, fewer participants failed to observe harm reduction techniques when handling drug “works”:  A smaller proportion shared their injection equipment and cookers with others, and more cleaned their equipment with bleach.

In an unexplained quirk, the buprenorphine group increased its rate of injecting methamphetamine, while such use dropped in the methadone group.

Both groups reported a reduction in the number of sexual partners. However, while women’s number of sexual partners dropped regardless of which treatment group they were in, the figure for men increased in the buprenorphine group and dropped in the methadone group.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, injection drug use, opioid substitution therapy, methadone, buprenorphine-naloxone, Jounral of Acquired Immune Deficiency Syndromes, aidsmap.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.